angiogenesis inhibitor

(redirected from Anti-angiogenic)
Also found in: Dictionary, Medical, Wikipedia.
Related to Anti-angiogenic: antiangiogenesis factor, Tumor Angiogenesis Factor
  • noun

Words related to angiogenesis inhibitor

a drug that is designed to prevent the growth of blood vessels that nourish tumors

References in periodicals archive ?
Earlier this year, Genetix reported that tumors themselves can be genetically engineered to secrete these and other anti-angiogenic proteins and thereby cause their own demise.
Also, since bevacizumab is an anti-angiogenic and inhibits blood flow to tumors, this trial will analyze the vascular effects of bevacizumab with chemotherapy.
After a preliminary scientific evaluation of AE-941, comparing its biological activities and safety profile to other anti-angiogenic products, the partner has agreed to enter into this co-development project.
Thus combining these two agents with distinct but complementary anti-angiogenic mechanisms provides synergistic anti-tumor effects and completely eradicates tumors resulting in dramatic cures and improvement in survival.
These findings demonstrate the potential utility of intramuscular delivery of a formulated plasmid for the treatment of disseminated cancers using any anti-angiogenic factor and not only endostatin.
Table 55: Anti-angiogenic Drug Target Mix for the Treatment of Nasopharyngeal Cancer According to the Compound Type and Developmental Stage of Drug
In the current study, however, researchers treated the mice only with rRp450 and the anti-angiogenic drug bevacizumab.
Tumor specificity of anti-angiogenic agents (Rixe, Kelly, Giaccone)
The CD-ROM searchable database reflects the most recent advances in the field of anti-angiogenic drug development, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes.
P529 is a non-steroidal, synthetic, small molecule dual acting anti-angiogenic and direct anti-tumor agent created through computational design, synthetic and medicinal chemistry, the result of three generations of Palomid design work.
today announced new data highlighting the anti-angiogenic and tumor-targeting properties of TM601 in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO).
April 11 /PRNewswire/ -- Researchers at Southern Research Institute today announced that they have developed a novel mouse model and in vitro and in vivo assays to help preclinical drug researchers in the discovery of anti-angiogenic agents for cancer treatment.
today announced that new data highlighting the anti-angiogenic and tumor-targeting properties of TM601 will be discussed in a poster presentation and in a published abstract at the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), being held May 29-June 2, 2009 in Orlando, FL.
Food and Drug Administration to study its anti-angiogenic drug, A6, in patients with advanced gynecologic cancers.